Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Melanoma musings: Dr Ascierto’s trial updates from ESMO

Paolo Ascierto • 1 Oct 2019
ESMO 2019
Melanoma Skin Cancer Dabrafenib Ipilimumab Nivolumab Pembrolizumab Trametinib

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, examines and explains the key melanoma updates from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Ascierto touches on various combination therapies, including ipilimumab and nivolumab in the treatment of stage IV, high-risk melanoma patients and the triplet combination of dabrafenib, trametinib, and pembrolizumab.

More from Paolo Ascierto

2:03
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
Paolo Ascierto • 21 Oct 2023
2:03
7-year results from CheckMate 238: adjuvant nivolumab in melanoma
Paolo Ascierto • 21 Oct 2023
2:38
Updates in melanoma at ESMO 2022
Paolo Ascierto • 12 Sep 2022
2:14
Standard-of-care and future research directions for advanced squamous cell carcinoma
Paolo Ascierto • 12 Sep 2022

Related Videos

2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
1:20
Can ctDNA guide the treatment decision making process in melanoma?
Christoffer Gebhardt • 9 Apr 2024
1:18
Elucidating ICI resistance in melanoma with ctDNA and tumor profiling
Christoffer Gebhardt • 9 Apr 2024
1:48
Ultra-sensitive ctDNA monitoring predicts ICI response in melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals